# Primary Progesterone Therapy for Operable Breast Cancer

> **NCT00123669** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tata Memorial Hospital** · enrollment: 1000 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** 500 mg of depot hydroxy-progesterone

## Key facts

- **NCT ID:** NCT00123669
- **Lead sponsor:** Tata Memorial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2020-05-29
- **Final completion:** 2020-05-29
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2020-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123669, "Primary Progesterone Therapy for Operable Breast Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00123669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*